Development of a highly sensitiveimmunochemiluminometric assay for prostate-specific antigen

George G. Klee, Carol M. Preissner, Joseph Eoesterling

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objectives.: An assay is described for measuring very low concentrations of prostate-specific antigen (PSA) which could be used to reliably monitor patients with radical prostatectornies potentially to detect early recurrence of prostate cancer. Methods.: A combination of immobilized and acridinium ester-labeled monoclonal antibodies was used to develop a two-step, 90-minute chemiluminometric assay. The reference standards for the serum assays were prepared by adding patient sera with a high concentration of PSA to base pools of female sera, which were selected because of low background counts and good recovery of added PSA. The assay was standardized to match the Abbott IMx PSA Assay. Results.: The serum-based analytic detection limit (calculated as response 2.5 standard deviations [SD] above the zero standard) is 0.004 ng/mL, whereas the "biologic detection limit" (calculated as 2.0 SD above the analytic detection limit) is 0.008 ng/mL. The assay is highly reproducible with interassay coefficients of variation (CV) under 12% down to 0.02 ng/mL, qualifying this as a "second generation" assay (eg, CV < 20% at 0.05 ng/mL). Conclusions.: This assay can measure very low concentrations of PSA in plasma and a wide range of PSA concentrations in urine. This assay will provide a valuable analytic tool for the future evaluation of the clinical utility of "ultrasensitive" PSA measurements for the management of prostate cancer.

Original languageEnglish (US)
Pages (from-to)76-82
Number of pages7
JournalUrology
Volume44
Issue number1
DOIs
StatePublished - 1994

Fingerprint

Prostate-Specific Antigen
Limit of Detection
Serum
Prostatic Neoplasms
Esters
Monoclonal Antibodies
Urine
Recurrence

ASJC Scopus subject areas

  • Urology

Cite this

Development of a highly sensitiveimmunochemiluminometric assay for prostate-specific antigen. / Klee, George G.; Preissner, Carol M.; Eoesterling, Joseph.

In: Urology, Vol. 44, No. 1, 1994, p. 76-82.

Research output: Contribution to journalArticle

Klee, George G. ; Preissner, Carol M. ; Eoesterling, Joseph. / Development of a highly sensitiveimmunochemiluminometric assay for prostate-specific antigen. In: Urology. 1994 ; Vol. 44, No. 1. pp. 76-82.
@article{cb9d6bb42b2c444c8e0967b886db7fbc,
title = "Development of a highly sensitiveimmunochemiluminometric assay for prostate-specific antigen",
abstract = "Objectives.: An assay is described for measuring very low concentrations of prostate-specific antigen (PSA) which could be used to reliably monitor patients with radical prostatectornies potentially to detect early recurrence of prostate cancer. Methods.: A combination of immobilized and acridinium ester-labeled monoclonal antibodies was used to develop a two-step, 90-minute chemiluminometric assay. The reference standards for the serum assays were prepared by adding patient sera with a high concentration of PSA to base pools of female sera, which were selected because of low background counts and good recovery of added PSA. The assay was standardized to match the Abbott IMx PSA Assay. Results.: The serum-based analytic detection limit (calculated as response 2.5 standard deviations [SD] above the zero standard) is 0.004 ng/mL, whereas the {"}biologic detection limit{"} (calculated as 2.0 SD above the analytic detection limit) is 0.008 ng/mL. The assay is highly reproducible with interassay coefficients of variation (CV) under 12{\%} down to 0.02 ng/mL, qualifying this as a {"}second generation{"} assay (eg, CV < 20{\%} at 0.05 ng/mL). Conclusions.: This assay can measure very low concentrations of PSA in plasma and a wide range of PSA concentrations in urine. This assay will provide a valuable analytic tool for the future evaluation of the clinical utility of {"}ultrasensitive{"} PSA measurements for the management of prostate cancer.",
author = "Klee, {George G.} and Preissner, {Carol M.} and Joseph Eoesterling",
year = "1994",
doi = "10.1016/S0090-4295(94)80013-8",
language = "English (US)",
volume = "44",
pages = "76--82",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Development of a highly sensitiveimmunochemiluminometric assay for prostate-specific antigen

AU - Klee, George G.

AU - Preissner, Carol M.

AU - Eoesterling, Joseph

PY - 1994

Y1 - 1994

N2 - Objectives.: An assay is described for measuring very low concentrations of prostate-specific antigen (PSA) which could be used to reliably monitor patients with radical prostatectornies potentially to detect early recurrence of prostate cancer. Methods.: A combination of immobilized and acridinium ester-labeled monoclonal antibodies was used to develop a two-step, 90-minute chemiluminometric assay. The reference standards for the serum assays were prepared by adding patient sera with a high concentration of PSA to base pools of female sera, which were selected because of low background counts and good recovery of added PSA. The assay was standardized to match the Abbott IMx PSA Assay. Results.: The serum-based analytic detection limit (calculated as response 2.5 standard deviations [SD] above the zero standard) is 0.004 ng/mL, whereas the "biologic detection limit" (calculated as 2.0 SD above the analytic detection limit) is 0.008 ng/mL. The assay is highly reproducible with interassay coefficients of variation (CV) under 12% down to 0.02 ng/mL, qualifying this as a "second generation" assay (eg, CV < 20% at 0.05 ng/mL). Conclusions.: This assay can measure very low concentrations of PSA in plasma and a wide range of PSA concentrations in urine. This assay will provide a valuable analytic tool for the future evaluation of the clinical utility of "ultrasensitive" PSA measurements for the management of prostate cancer.

AB - Objectives.: An assay is described for measuring very low concentrations of prostate-specific antigen (PSA) which could be used to reliably monitor patients with radical prostatectornies potentially to detect early recurrence of prostate cancer. Methods.: A combination of immobilized and acridinium ester-labeled monoclonal antibodies was used to develop a two-step, 90-minute chemiluminometric assay. The reference standards for the serum assays were prepared by adding patient sera with a high concentration of PSA to base pools of female sera, which were selected because of low background counts and good recovery of added PSA. The assay was standardized to match the Abbott IMx PSA Assay. Results.: The serum-based analytic detection limit (calculated as response 2.5 standard deviations [SD] above the zero standard) is 0.004 ng/mL, whereas the "biologic detection limit" (calculated as 2.0 SD above the analytic detection limit) is 0.008 ng/mL. The assay is highly reproducible with interassay coefficients of variation (CV) under 12% down to 0.02 ng/mL, qualifying this as a "second generation" assay (eg, CV < 20% at 0.05 ng/mL). Conclusions.: This assay can measure very low concentrations of PSA in plasma and a wide range of PSA concentrations in urine. This assay will provide a valuable analytic tool for the future evaluation of the clinical utility of "ultrasensitive" PSA measurements for the management of prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0028244093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028244093&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(94)80013-8

DO - 10.1016/S0090-4295(94)80013-8

M3 - Article

C2 - 7518985

AN - SCOPUS:0028244093

VL - 44

SP - 76

EP - 82

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -